Vaccine stocks jumped in premarket trading,with Novavax rising over 5% and BioNTech SE rising more than 3%

Vaccine stocks jumped in premarket trading,with Novavax rising over 5% and BioNTech SE rising more than 3%.Three doses of the Pfizer-BioNTechCOVID-19vaccine, BNT162b2 have been shown in a preliminary study to neutralize the Omicron variant.

In a press release, Pfizer and BioNTech have announced that serum antibodies induced after three doses of their COVID-19 vaccine (BNT162b2) are able to neutralize the Omicron variant.

The company’s laboratory study involved testing human sera obtained from the blood of individuals who had received two or three 30-µg doses of the BNT162B2 using a pseudovirus neutralization test, which was used to study the effect of antibodies to neutralize the capability of viruses to enter cells and thus prevent infection. The sera were collected from subjects 3 weeks after receiving the second dose or one month after receiving the third dose of their vaccine.